Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Single agent and combination checkpoint inhibitors therapy: A post marketing safety analysis.
Authors
Rawad Elias
Boston Medical Center, Boston, MA
Rawad Elias, Jennifer Rider, Xainming Tan, Osama E. Rahma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Age-Related Side Effects
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 125)
DOI
10.1200/JCO.2018.36.5_suppl.125
Abstract #
125
Poster Bd #
G1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.
First Author: Emilia Nan Tie
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2020 ASCO Virtual Scientific Program
Is there a benefit of immune checkpoint inhibitors for patients over 75 years of age with advanced cancer in first and second line setting: A meta-analysis.
First Author: Thierry Landre
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya